Anavex Life Sciences Corp. (0HFR.L)
USD 9.46
(-2.94%)
USD 9.46
(-2.94%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | - USD | 0.0% |
| 2022 | - USD | 0.0% |
| 2021 | - USD | 0.0% |
| 2020 | - USD | 0.0% |
| 2019 | - USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | -100.0% |
| 2015 | 85.57 Thousand USD | -98.55% |
| 2014 | 5.91 Million USD | 2703.62% |
| 2013 | 210.86 Thousand USD | -29.48% |
| 2012 | 299 Thousand USD | -65.55% |
| 2011 | 867.91 Thousand USD | -65.18% |
| 2010 | 2.49 Million USD | -0.57% |
| 2009 | 2.5 Million USD | 61.71% |
| 2008 | 1.55 Million USD | 0.0% |
| 2007 | - USD | -100.0% |
| 2006 | 20 Thousand USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | - USD | 0.0% |
| 2024 Q1 | - USD | 0.0% |
| 2024 Q2 | - USD | 0.0% |
| 2023 Q3 | - USD | 0.0% |
| 2023 Q4 | - USD | 0.0% |
| 2023 FY | - USD | 0.0% |
| 2023 Q1 | - USD | 0.0% |
| 2023 Q2 | - USD | 0.0% |
| 2022 Q3 | - USD | 0.0% |
| 2022 FY | - USD | 0.0% |
| 2022 Q4 | - USD | 0.0% |
| 2022 Q1 | - USD | 0.0% |
| 2022 Q2 | - USD | 0.0% |
| 2021 Q1 | - USD | 0.0% |
| 2021 FY | - USD | 0.0% |
| 2021 Q2 | - USD | 0.0% |
| 2021 Q3 | - USD | 0.0% |
| 2021 Q4 | - USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2020 FY | - USD | 0.0% |
| 2020 Q2 | - USD | 0.0% |
| 2020 Q3 | - USD | 0.0% |
| 2020 Q4 | - USD | 0.0% |
| 2019 Q2 | - USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2019 Q4 | - USD | 0.0% |
| 2019 FY | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2016 FY | - USD | -100.0% |
| 2016 Q1 | 82.67 Thousand USD | -3.38% |
| 2016 Q2 | 88.48 Thousand USD | 7.02% |
| 2016 Q4 | - USD | -100.0% |
| 2016 Q3 | 88.23 Thousand USD | -0.28% |
| 2015 Q1 | 5.25 Million USD | -11.07% |
| 2015 Q3 | 107.4 Thousand USD | -52.08% |
| 2015 FY | 85.57 Thousand USD | -98.55% |
| 2015 Q2 | 224.13 Thousand USD | -95.74% |
| 2015 Q4 | 85.57 Thousand USD | -20.33% |
| 2014 Q1 | 200.36 Thousand USD | -4.98% |
| 2014 Q2 | 194.73 Thousand USD | -2.81% |
| 2014 Q3 | 201.92 Thousand USD | 3.69% |
| 2014 Q4 | 5.91 Million USD | 2827.7% |
| 2014 FY | 5.91 Million USD | 2703.62% |
| 2013 Q2 | 761.29 Thousand USD | 27.09% |
| 2013 Q3 | 757.6 Thousand USD | -0.48% |
| 2013 FY | 210.86 Thousand USD | -29.48% |
| 2013 Q1 | 599 Thousand USD | 100.33% |
| 2013 Q4 | 210.86 Thousand USD | -72.17% |
| 2012 Q2 | 1.2 Million USD | 3.86% |
| 2012 Q1 | 1.15 Million USD | 33.2% |
| 2012 FY | 299 Thousand USD | -65.55% |
| 2012 Q4 | 299 Thousand USD | 510.2% |
| 2012 Q3 | 49 Thousand USD | -95.92% |
| 2011 FY | 867.91 Thousand USD | -65.18% |
| 2011 Q4 | 867.91 Thousand USD | 4.83% |
| 2011 Q1 | 200 Thousand USD | -91.98% |
| 2011 Q3 | 827.9 Thousand USD | 313.95% |
| 2011 Q2 | 200 Thousand USD | 0.0% |
| 2010 FY | 2.49 Million USD | -0.57% |
| 2010 Q2 | 3.58 Million USD | 40.28% |
| 2010 Q3 | 3.56 Million USD | -0.43% |
| 2010 Q1 | 2.55 Million USD | 1.83% |
| 2010 Q4 | 2.49 Million USD | -30.09% |
| 2009 Q1 | 1.68 Million USD | 8.68% |
| 2009 Q4 | 2.5 Million USD | -0.68% |
| 2009 Q3 | 2.52 Million USD | 25.86% |
| 2009 Q2 | 2 Million USD | 19.04% |
| 2009 FY | 2.5 Million USD | 61.71% |
| 2008 Q3 | 1.29 Million USD | 92.01% |
| 2008 Q1 | 200 Thousand USD | 0.0% |
| 2008 Q4 | 1.55 Million USD | 19.59% |
| 2008 FY | 1.55 Million USD | 0.0% |
| 2008 Q2 | 675 Thousand USD | 237.5% |
| 2007 Q4 | - USD | -100.0% |
| 2007 Q2 | 85 Thousand USD | 325.0% |
| 2007 Q1 | 20 Thousand USD | 0.0% |
| 2007 Q3 | 273 Thousand USD | 221.18% |
| 2007 FY | - USD | -100.0% |
| 2006 Q3 | 20 Thousand USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q4 | 20 Thousand USD | 0.0% |
| 2006 FY | 20 Thousand USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Imunon, Inc. | 1.13 Million USD | 100.0% |
| Homology Medicines, Inc. | 44.05 Million USD | 100.0% |
| uniQure N.V. | 138.4 Million USD | 100.0% |
| Abeona Therapeutics Inc. | 4.4 Million USD | 100.0% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | 100.0% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | 100.0% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | 100.0% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | 100.0% |
| bluebird bio, Inc. | 330.32 Million USD | 100.0% |
| Blueprint Medicines Corporation | 774.12 Million USD | 100.0% |
| Cara Therapeutics, Inc. | 43.16 Million USD | 100.0% |
| Adicet Bio, Inc. | 17.7 Million USD | 100.0% |
| Dynavax Technologies Corporation | 256.91 Million USD | 100.0% |
| Editas Medicine, Inc. | 36.53 Million USD | 100.0% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | 100.0% |
| Geron Corporation | 85.89 Million USD | 100.0% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 100.0% |
| Illumina, Inc. | 2.26 Billion USD | 100.0% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | 100.0% |
| IQVIA Holdings Inc. | 14.23 Billion USD | 100.0% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 100.0% |
| Myriad Genetics, Inc. | 145 Million USD | 100.0% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 100.0% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | 100.0% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | 100.0% |
| Verastem, Inc. | 41.55 Million USD | 100.0% |
| Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 100.0% |
| Waters Corporation | 2.35 Billion USD | 100.0% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | 100.0% |
| Thermo Fisher Scientific Inc. | 34.91 Billion USD | 100.0% |
| Biogen Inc. | 7.33 Billion USD | 100.0% |
| Nektar Therapeutics | 230.4 Million USD | 100.0% |
| Viking Therapeutics, Inc. | 1.26 Million USD | 100.0% |
| Perrigo Company plc | 4.07 Billion USD | 100.0% |
| Unity Biotechnology, Inc. | 26.99 Million USD | 100.0% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | 100.0% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | 100.0% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | 100.0% |
| Evolus, Inc. | 126.54 Million USD | 100.0% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 100.0% |
| FibroGen, Inc. | 170.45 Million USD | 100.0% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 100.0% |
| OPKO Health, Inc. | 326.56 Million USD | 100.0% |
| Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 100.0% |
| Exelixis, Inc. | 189.94 Million USD | 100.0% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | 100.0% |
| Zoetis Inc. | 6.8 Billion USD | 100.0% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | 100.0% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | 100.0% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 100.0% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | 100.0% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 100.0% |
| Insmed Incorporated | 1.2 Billion USD | 100.0% |
| TG Therapeutics, Inc. | 110.79 Million USD | 100.0% |
| Incyte Corporation | 38.28 Million USD | 100.0% |
| Emergent BioSolutions Inc. | 877.5 Million USD | 100.0% |